Your Industry
Life Sciences & Biotech
Accelerating Predictable, Profitable Performance in Life Sciences & Biotech
We accelerate performance across development, supply chains, and operations, turning uncertainty into controlled, measurable performance.
The sector is operating under increasing pressure:
- Long development cycles and time-to-market challenges
- Supply chain complexity and scalability constraints
- Rising costs and capital efficiency demands
- Operational transition from R&D to commercial scale
At the same time, innovation expectations and competitive pressures continue to increase.
Brooks International addresses CEO challenges and translates growth into predictable, profitable performance.
Where We Drive Operational and Financial Performance
Life Sciences & Biotech performance is measured by how quickly, confidently, and efficiently programs advance from discovery through clinical development, regulatory milestones, partner transfer, and commercialization readiness.
With funding runway, development spend, trial execution, outsourced networks, GxP readiness, and supply continuity under constant pressure, enterprise value creation comes from reducing cycle time, improving resource utilization, protecting quality, and converting milestone progress into commercial and financial outcomes.
Program, Portfolio, and Milestone Execution
Strengthen execution across research, preclinical, clinical, regulatory, and commercialization programs by improving governance, milestone tracking, cross-functional coordination, issue escalation, resource alignment, and spend visibility.
Value Impact
Accelerates value-creating milestones, improves capital allocation, reduces execution drag, and strengthens investor, partner, and leadership confidence.
Clinical Trial Execution and Site Performance
Improve trial performance by strengthening enrollment planning, site activation, patient recruitment, vendor coordination, data readiness, protocol adherence, and visibility into delays, risks, and handoffs.
Value Impact
Reduces trial cycle time, protects development spend, improves milestone predictability, and accelerates the path to regulatory and commercial value.
Quality, Regulatory, and GxP Readiness
Strengthen regulated execution by improving documentation control, procedural adherence, audit readiness, data integrity, CAPA closure, training effectiveness, and escalation of quality or compliance risks.
Value Impact
Reduces regulatory exposure, protects program continuity, improves operating consistency, and prevents avoidable quality issues from delaying value creation.
Lab, Technical Operations, and Manufacturing Optimization
Improve performance across laboratories, process development, pilot operations, manufacturing, testing, and technical support functions by strengthening scheduling, resource utilization, equipment readiness, workflow discipline, and execution accountability.
Value Impact
Improves cycle time, reduces operating cost, increases throughput, and converts specialized scientific and technical capacity into stronger milestone and financial performance.
Partner, Supply Chain, and Material Readiness
Improve coordination across CROs, CDMOs, suppliers, logistics partners, labs, materials, reagents, components, and clinical or commercial supply while reducing shortages, delays, and working capital drag.
Value Impact
Protects study continuity, product availability, cash generation, and service reliability across internal and outsourced operating networks.
Launch, Scale-Up, and Capital Execution
Strengthen governance over technology transfer, validation, clinical-to-commercial scale-up, facility readiness, automation, commercialization planning, and capital investments from approval through benefit realization.
Value Impact
Accelerates revenue activation, improves capital productivity, reduces launch and scale-up risk, and ensures investment translates into measurable operational and financial outcomes.
All performance improvement is delivered through the Brooks International Performance Engine™ - our system for connecting strategy, financial outcomes, and execution.
Success Stories
Benefit from our deep experience in delivering accelerated value across complex operating environments in Life Sciences & Biotech
Proven Results in Life Science & Biotech
Leading Global Industrial Biotechnology Producer Redesigns Supply Chain, Reducing Total Inventory by 54% and Consolidating 60% of Distribution Centers
- $17M Annualized EBITDA Improvement
- 60% Distribution Center Consolidation
- 54% Total Inventory Reduction
- 38% Distribution Cost Reduction
- 10% Supply Chain Labor Cost Reduction
Division of Leading Worldwide Provider of Advanced Life Sciences Products Builds Predictable Manufacturing Capability, Increasing Throughput 18% and Achieving Safety Stock Targets During a Critical Product Transition
- 100% Safety Stock Inventory Target Achieved
- 18% Throughput Increase
- $5M Annualized EBITDA Improvement
Latest Life Sciences & Biotech Insights
Cell and Gene Therapy’s Next Phase: From Regulatory Flexibility to Scalable Delivery
Life Sciences & Biotech
The Biotech Capital Reset: Why Funding Now Rewards De-Risked Execution
Life Sciences & Biotech
BIOSECURE and the Biotech Supply Chain: Rebuilding Resilience Without Slowing Science
Life Sciences & Biotech